SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Dollar tax payments and startup grants: Israel's new plan to protect tech

YL Ventures: “The companies retaining talent have replaced the performance of care with the practice of it”

Amdocs begins cutting jobs in Israel as global layoff plan moves forward

Israeli tech firms drive over 500 open roles in New York

Buzz

Most popular

Daily

Weekly

1

AppsFlyer raises over $1 billion from Google, Meta, Unity and Moloco at a $2.7 billion valuation

2

AI startup Engram raises $98 million at $600 million valuation with just 13 employees

3

Intel CEO praises Israel’s tech sector: “Very disruptive and innovative”

4

How Chinese cars became a national security issue in Israel

5

Anduril explores Israeli expansion as defense-tech boom accelerates

Stock

6 stories about Stock

ד"ר אמיר ולדמן מייסדי הום סקינוביישנס מעורב בפרשת מובילאיי

Emails in Mobileye Insider Trading Case Pinpoint Leak’s Source

18.12.17|Tomer Ganon and Ran Abramson

The documents show how defendants communicated information about the stock’s expected spike

ד"ר אמיר ולדמן מייסדי הום סקינוביישנס מעורב בפרשת מובילאיי

Israeli Defendant Denies Mobileye Insider Trading Charges

08.12.17|Tomer Ganon and Ran Abramson

Amir Waldman, former vice president of Israel-based medical device company Syneron Medical, is being accused by the SEC of making over $4 million from insider trading in Mobileye securities

Allergan to Sell Teva Shares to J.P. Morgan

14.11.17|Dror Reich and Lilach Baumer

Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018

MediWound Loses Stock Purchase Agreement Case

14.11.17|Dror Reich

The burn and wound treatment company was ordered to follow through on previous agreement to buy shares of biotech company Polyheal

מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer

For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.

מטה טבע פתח תקווה

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer

The stem-cell therapy company diluted Teva’s shares through a new offering in August

Previous Articles